Meeting Banner
Abstract #3747

Monitoring neoadjuvant chemotherapy in breast cancer patients using CEST and 31P-MRS at 7 tesla

Erwin Krikken1, Vitaliy Khlebnikov1, Moritz Zaiss2, Wybe J.M. van der Kemp1, Tijl A. van der Velden1, Hanneke W.M. van Laarhoven3, Dennis W.J. Klomp1, and Jannie P. Wijnen1

1Radiology, UMC Utrecht, Utrecht, Netherlands, 2Max Planck Institute for Biological Cybernetics, Tubingen, Germany, 3Oncology, Amsterdam Medical Center, Amsterdam, Netherlands

Treatment monitoring is of importance for breast cancer patients receiving systemic therapy. Metabolic imaging methods such as CEST and 31P-MRS may have potential to predict treatment efficacy in an early stage of the treatment. In this study we assessed the amide proton transfer (APT) signal and the pH change in breast cancer patients before and after the first cycle of neoadjuvant chemotherapy to explore the relation between APT and pH. We observed changes in both the APT signal and the pH between the two measurements. These changes may serve as biomarkers for predicting treatment response to NAC in an early stage.

This abstract and the presentation materials are available to members only; a login is required.

Join Here